Patents by Inventor Christos Polytarchou

Christos Polytarchou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for diagnosis and prognosis of cancer and progression, and for screening anti-cancer agents
    Patent number: 8617818
    Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGF?-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1?/? mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: December 31, 2013
    Assignees: Tufts Medical Center, President and Fellows of Harvard College
    Inventors: Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos
  • COMPOSITIONS AND METHODS FOR DIAGNOSIS AND PROGNOSIS OF CANCER AND PROGRESSION, AND FOR SCREENING ANTI-CANCER AGENTS
    Publication number: 20120021983
    Abstract: MicroRNA (miRNA) profiling of cells showed unique miRNA signatures for each of three Akt isoforms. Among differentially regulated miRNA species, the miR-200 family was downregulated in Akt2-expressing cells. Akt1 knockdown inhibited expression of miR-200 and promoted TGF?-induced epithelial-mesenchymal-transition (EMT) and a stem cell like phenotype. Carcinomas developing in MMTV-cErb2/Akt1?/? mice exhibited increased invasiveness because of EMT induced by miR-200 downregulation. EMT was found to be controlled by miRNA species that are regulated by the balance between Akt1 and Akt2, rather than overall Akt levels.
    Type: Application
    Filed: September 30, 2011
    Publication date: January 26, 2012
    Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE, TUFTS MEDICAL CENTER, INC.
    Inventors: Philip N. Tsichlis, Christos Polytarchou, Dimitrios Iliopoulos